VOQUEZNA TRIPLE and DUAL PAKs Drug Insight and Market Forecast - 2032

VOQUEZNA TRIPLE and DUAL PAKs Drug Insight and Market Forecast − 2032

“VOQUEZNA TRIPLE and DUAL PAKs Drug Insight and Market Forecast – 2032” report provides comprehensive insights about VOQUEZNA TRIPLE and DUAL PAKs for Helicobacter pylori (H. pylori) infection in the United States. A detailed picture of the VOQUEZNA TRIPLE and DUAL PAKs for H. pylori in the United States for the study period 2019 –2032 is provided in this report along with a detailed description of the VOQUEZNA TRIPLE and DUAL PAKs for H. pylori. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the VOQUEZNA TRIPLE and DUAL PAKs market forecast analysis for H. pylori in the US, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in H. pylori.

Drug Summary

VOQUEZNA TRIPLE and DUAL PAKs developed by Phathom Pharmaceuticals are co-packaged products containing potassium-competitive acid blockers (P-CABs) in combination with antibiotics for the treatment of H. pylori infection in adults.

VOQUEZNA TRIPLE PAK contains vonoprazan, a PCAB, with amoxicillin, a penicillin class antibacterial with a broad spectrum of bactericidal activity against many gram-positive and gram-negative microorganisms, and clarithromycin, a semi-synthetic macrolide antimicrobial for oral use, while, the DUAL PAK contains vonoprazan and amoxicillin only.

Vonoprazan is the first novel acid suppressant from a new drug class to be approved in the US in over 30 years. However, it is approved for the treatment of H. pylori infection and other acid-related diseases in many countries, including Japan.

Vonoprazan rapidly increases intragastric pH and maintains it to a greater degree than PPIs, leading to higher H. pylori eradication rates. Compared to PPI lansoprazole triple therapy, vonoprazan containing VOQUEZNA treatment regimens demonstrated superior eradication rates in various clinical trials for treating H. pylori infection in adults.

Phathom pharmaceutical is also developing vonoprazan-based regimes for the treatment of erosive esophagitis (EE), for which it has submitted an NDA to the FDA, and non-erosive reflux disease (NERD).

Scope of the Report

The report provides insights into:

A comprehensive product overview including the VOQUEZNA TRIPLE and DUAL PAKs description, mechanism of action, dosage and administration, research and development activities in H. pylori.

Elaborated details on VOQUEZNA TRIPLE and DUAL PAKs regulatory milestones and other development activities have been provided in this report.

The report also highlights the VOQUEZNA TRIPLE and DUAL PAKs research and development activities in H. pylori across the United States.

The report also covers the patents information with expiry timeline around VOQUEZNA TRIPLE and DUAL PAKs.

The report contains forecasted sales of VOQUEZNA TRIPLE and DUAL PAKs for H. pylori till 2032.

Comprehensive coverage of the late-stage emerging therapies for H. pylori.

The report also features the SWOT analysis with analyst views for VOQUEZNA TRIPLE and DUAL PAKs in H. pylori.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

VOQUEZNA TRIPLE and DUAL PAKs Analytical Perspective by DelveInsight

In-depth VOQUEZNA TRIPLE and DUAL PAKs Market Assessment

This report provides a detailed market assessment of VOQUEZNA TRIPLE and DUAL PAKs for H. pylori in the United States. This segment of the report provides forecasted sales data from 2023 to 2032.

VOQUEZNA TRIPLE and DUAL PAKs Clinical Assessment

The report provides the clinical trials information of VOQUEZNA TRIPLE and DUAL PAKs for H. pylori covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

In the coming years, the market scenario for H. pylori is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence VOQUEZNA TRIPLE and DUAL PAKs dominance.

Other emerging products for H. pylori are expected to give tough market competition to VOQUEZNA TRIPLE and DUAL PAKs and launch of late-stage emerging therapies in the near future will significantly impact the market.

A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of VOQUEZNA TRIPLE and DUAL PAKs in H. pylori.

Our in-depth analysis of the forecasted sales data of VOQUEZNA TRIPLE and DUAL PAKs from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the VOQUEZNA TRIPLE and DUAL PAKs in H. pylori.

Key Questions

What is the product type, route of administration and mechanism of action of VOQUEZNA TRIPLE and DUAL PAKs?

What is the clinical trial status of the study related to VOQUEZNA TRIPLE and DUAL PAKs in H. pylori and study completion date?

What are the key collaborations, mergers and acquisitions, licensing and other activities related to the VOQUEZNA TRIPLE and DUAL PAKs development?

What are the key designations that have been granted to VOQUEZNA TRIPLE and DUAL PAKs for H. pylori?

What is the forecasted market scenario of VOQUEZNA TRIPLE and DUAL PAKs for H. pylori?

What are the forecasted sales of VOQUEZNA TRIPLE and DUAL PAKs in the United States?

What are the other emerging products available and how are these giving competition to VOQUEZNA TRIPLE and DUAL PAKs for H. pylori?

Which are the late-stage emerging therapies under development for the treatment of H. pylori?